We are pleased to announce the next chapter of our exciting journey as a disruptive innovator in clinical diagnostics: Quotient is becoming AliveDx. AliveDx is more than a name, it is a call to action. AliveDx brings urgency to the work that we do as leaders in innovation and healthcare. When we become ‘alive,’ we do more than just live — we give energy, meaning, and purpose to our life. We believe faster diagnosis must be a top priority for clinical diagnostics. Developing innovative testing methods to reduce the time to diagnosis stops the long-term negative consequences for those living with autoimmune diseases. Faster disease detection prevents life-threatening health outcomes and brings peace of mind to patients. Not only must we support life, but help people to live better. Our mission is to empower diagnostic insights, transform patient care, and innovate for life. Our products, Alba and MosaiQ, have already demonstrated valuable contributions in the areas of transfusion and clinical diagnostics. We will continue to innovate and deliver more products for our customers as AliveDx. Join us as we come alive together in this next chapter and stay tuned for our full AliveDx brand launch this fall.
Quotient is becoming AliveDx
Trending Topics
Our passion for the work we do is matched only by our commitment to consistently provide the best customer experience possible.
-
AliveDx Suisse S.A. and Patho Solutions Malaysia Sdn. Bhd. sign Distribution Agreement in Malaysia
AliveDx Suisse S.A. and Patho Solutions Malaysia Sdn. Bhd. have signed a distribution agreement, which will enable Patho Solutions Malaysia to distribute the MosaiQ® solution in Malaysia. The distribution agreement takes effect immediately. AliveDx is dedicated to expanding its reach
-
AliveDx Suisse S.A. and Everlight Biotech Co Ltd. Sign Distribution Agreement in Taiwan
AliveDx Suisse S.A. and Everlight Biotech Co. Ltd. have signed a distribution agreement, which will enable Everlight Biotech Co. Ltd. to distribute the MosaiQ® solution in Taiwan. The distribution agreement takes effect immediately. AliveDx is dedicated to expanding its reach
-
Presenting the AliveDx 2023 Sustainability Report
At AliveDx, we understand that the success of our business is closely linked to the wellbeing of the communities in which we operate. Our goal is to advance sustainable practices in every aspect of our operations. We are pleased to
-
AliveDx Suisse S.A. and Ozgun Kimya A.S. Sign Distribution Agreement in Türkiye
AliveDx Suisse S.A. and Ozgun Kimya A.S. have signed a distribution agreement, which will enable Ozgun Kimya A.S. to distribute the MosaiQ® solution in Türkiye. The distribution agreement takes effect immediately. This strategic partnership reaffirms AliveDx’s consistent commitment to grow
-
MosaiQ® AiPlex CTD Solution Now Available in Over 35 Countries
We are excited to announce that our recently CE-marked MosaiQ® AiPlex CTD microarray immunoassay, which aims to shorten time-to-diagnosis for autoimmune patients, is now available in over 35 markets across Europe and the Asia Pacific region. The MosaiQ AiPlex CTD
-
Bringing AliveDx’s ESG Activities and Commitments to Life
Our leadership team recently gathered to celebrate 2023 achievements and kick off the new year. As part of a highly energizing team-building activity, and to bring our environmental, social and governance commitments to life, the team built solar lamps that
